INTRODUCTION
The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, has been steadily increasing over the years, posing a serious threat to the well-being of people worldwide[1-4]. Therefore, there is an urgent need to develop an effective therapy for MASLD[5]. Natural products have been garnering significant attention because of their multi-targeted actions and favorable safety profiles. A recent study by Gao et al[6], published in the World Journal of Gastroenterology, titled “Allyl isothiocyanate ameliorates metabolic dysfunction-associated steatotic liver disease via vitamin D receptors in hepatocytes”, describes a novel mechanism through which a bioactive compound from cruciferous vegetables—allyl isothiocyanate (AITC)—ameliorates MASLD by activating the vitamin D receptor (VDR). This study by Gao et al[6] deepens our understanding of the pharmacological actions of AITC. At the same time, and, more importantly, it forges a compelling link between two seemingly disparate pathways—natural product signaling and vitamin D (VD) metabolism—thereby opening new avenues for MASLD drug discovery.
CORE DISCOVERIES AND CLINICAL IMPLICATIONS
Complexity of MASLD and the therapeutic potential of natural products
The pathophysiology of MASLD has long evolved beyond the simplistic notion of “fatty liver”[7]. Evolving from the classic “two-hit” hypothesis to the contemporary “multiple-hit” model, the pathogenesis of MASLD involves a complex interplay of factors that disrupt the gut-liver axis. Factors such as hepatic fat accumulation, insulin resistance, lipotoxicity, and gut microbiota dysbiosis collectively contribute to impaired intestinal barrier function, increased permeability, and disease progression through various mechanisms such as mitochondrial dysfunction, endoplasmic reticulum stress, and chronic inflammation[8,9]. This complexity may explain why single-target drugs have poor efficacy and why many investigational compounds have a high rate of failure.
AITC, a compound commonly found in horseradish, has antimicrobial properties. As a result, it is attracting interest for use in food preservation and pharmaceutical applications[10]. Apart from its antimicrobial effects, AITC has also shown efficacy against various types of cancers. In addition, it is used as an antioxidant and anti-inflammatory agent for the treatment of numerous other diseases[11,12]. Research on MASLD using animal models has demonstrated that AITC alleviates hepatic steatosis and improves insulin resistance. These beneficial effects are driven by a multi-faceted mechanism: AITC activates the Sirt1/AMPKα pathway while inhibiting the nuclear factor-κB signaling pathway, leading to the downregulation of lipogenic factors such as SREBP1 and the upregulation of fatty acid β-oxidation[13]. High-dose AITC exerts adverse effects on peripheral organs in some animal models with severe metabolic abnormalities. Specific toxicological concerns arise from the potential off-target effects of AITC. For example, AITC at the highest dose decreases the levels of pancreatic amylase and lipase and causes thyroid gland hypertrophy in high-fat-diet-fed/streptozotocin diabetic rat models[14], warranting dose-response toxicology studies before the clinical translation of AITC. However, these known pathways are insufficient to fully elucidate the entirety of the benefits of AITC. Gao et al[6] address this critical knowledge gap by shifting the focus to a relatively novel player: The VDR.
VDR: A novel bridge connecting metabolic health and hepatic protection
VD has long been primarily associated with calcium-phosphate metabolism and bone health[15,16]. However, recent studies have revealed the widespread expression of its receptor, VDR, in various tissues, including the liver, and its crucial role in metabolic regulation[17]. Epidemiological data consistently show an inverse correlation between serum VD levels and the severity of MASLD[18]. MASLD subtypes (e.g., obese vs lean and diabetic vs non-diabetic)[18] may exhibit differential VDR expression or metabolic responses, necessitating the use of stratified approaches. Basic scientific research has further revealed that the deletion of VDR in hepatocytes or hepatic macrophages exacerbates hepatic lipid deposition, inflammation, and insulin resistance[19,20]. Critically, the role of VDR varies across liver cell types. Hepatocyte VDR activation promotes lipid export[19,20], while stellate cell VDR may drive fibrosis under chronic injury[19]. This cell-specific divergence urges caution—therapeutic VDR agonism must balance hepatoprotection against pro-fibrotic risks.
Of particular interest is the established interaction between VDR and hepatocyte nuclear factor 4 alpha (HNF-4α), a master transcriptional regulator of liver-specific genes. Downstream targets of HNF-4α include microsomal triglyceride transfer protein (MTTP) and apolipoprotein B (ApoB)—core components in the assembly and secretion of very-low-density lipoprotein (VLDL)[21]. VLDL is the primary vehicle for exporting hepatic-synthesized triglycerides out of the liver. Therefore, activating the VDR-HNF-4α axis could, in theory, enhance the lipid export capacity of the liver, thereby “unloading” the hepatocytes and alleviating lipid accumulation. This forms the central hypothesis that Gao et al[6] sought to validate.
Core findings of the study: Constructing the AITC-VDR-HNF-4α axis
The research design employed by Gao et al[6] is clear and methodical. They successfully established an in vitro MASLD model using the AML-12 mouse hepatocyte line treated with palmitic acid (PA), effectively mimicking key pathological features such as excessive lipid accumulation, upregulated lipogenesis, and impaired fatty acid β-oxidation. A critical breakthrough of this study lies in its systematic demonstration of a complete signaling pathway: AITC → VDR ↑ → HNF-4α/MTTP/ApoB ↑ → lipid export ↑ & lipogenesis ↓ & β-oxidation ↑ → MASLD amelioration.
Gao et al[6] first reconfirmed the protective effects of AITC: It significantly reduced PA-induced intracellular triglyceride levels and lipid droplet accumulation. Concurrently, it downregulated key lipogenic factors (SREBP1, SCD1, and ACC1), upregulated crucial drivers of fatty acid β-oxidation (PPARα and CPT1α), and improved insulin signaling (PI3K). These observations established the reliability of their model. Gao et al[6] made an intriguing observation: VDR expression is compensatorily upregulated in PA-induced steatotic hepatocytes. Treatment with AITC further significantly boosted VDR expression at both mRNA and protein levels. This observation directly suggested that the benefits of AITC might be linked to its ability to “empower” VDR. The next step in mechanistic exploration was the HNF-4α/MTTP/ApoB axis. The results showed that while PA treatment had little effect on HNF-4α itself, it significantly suppressed the expression of its downstream effectors, MTTP and ApoB. AITC treatment reversed this suppression, markedly increasing MTTP and ApoB protein levels. It was as if AITC, via VDR, had “unclogged” the lipid export “pipeline” blocked by PA.
To definitively establish the critical role of VDR in this pathway, the researchers used VD itself as a VDR agonist in combination experiments. The results were convincing: The combination of VD and AITC produced a synergistic “1 + 1 > 2” effect. The combination group outperformed the AITC alone group in reducing lipid accumulation, suppressing lipogenesis, promoting β-oxidation, and upregulating the HNF-4α/MTTP/ApoB pathway. This result strongly proves that the effects of AITC are indeed mediated by the VDR, and that enhancing VDR activity can directly amplify the therapeutic impact of AITC. However, VDR may not be the only pathway; the known Sirt1/AMPKα and NF-κB pathways[13] are likely to function simultaneously with VDR. These pathways may be synergistic or compensatory. The VDR activation mechanism (such as promoting lipid output) may work in synergy with the Sirt1/AMPKα-mediated improvement of oxidative stress and regulation of glucose and lipid metabolism, as well as the anti-inflammatory effect of NF-κB inhibition, collectively combating the multifactorial pathology of MASLD. Future research should focus on exploring the weights, interactions (cross-talk), and potential preferences for cell types or pathological stages of these different pathways.
Implications and future perspectives: Opportunities and challenges from bench to bedside
The study by Gao et al[6] has significant theoretical and clinical implications. Firstly, it provides a compelling example of “food as medicine”. AITC, a dietary-derived natural compound, has a safety profile validated by its long history of human consumption. Gao et al[6] provide a solid scientific foundation for exploring AITC as a candidate molecule for MASLD prevention or therapy. We posit that AITC-based nutraceuticals may offer a novel option. However, this requires rigorous validation of bioavailability, dosing, and safety in humans—gaps that are not addressed in the current study. Secondly, it deepens our understanding of the biological functions of VDR. Past research on the hepatoprotective roles of VDR generally focused on its anti-inflammatory and anti-fibrotic effects[22]. In contrast, Gao et al[6] highlight the direct role of VDR in regulating hepatic lipid homeostasis and export, positioning it as a critical metabolic regulator, not merely an anti-inflammatory factor. However, translating this discovery into clinical practice remains a long process.
The study has several inherent limitations too. The primary limitation is the lack of in vivo validation. The VDR-HNF-4α axis reported by this study is indeed an important intrahepatic mechanism. However, considering it as the entire picture of MASLD treatment is insufficient. The necessity of verifying the study results in a complex physiological environment has been emphasized, and the suggestions for future research are echoed. Overall efficacy and safety evaluations should be carried out in diet-induced obese mouse models, verified in patient-derived organoid models[23], and used in liver cell-specific VDR knockout mouse models to determine the absolute contribution of this pathway to the overall effect of AITC in a complex background of live animals. If the efficacy of AITC disappears upon VDR deletion in vivo, the causal relationship of this pathway would be most powerfully confirmed. Furthermore, the question of how AITC upregulates VDR expression remains a “black box”. Is it through direct transcriptional activation? Or is it mediated through its known action of activating the TRPA1 channel, causing calcium influx, and triggering downstream signals? Could it be an indirect effect via its antioxidant properties? Answering these questions will enable a more precise drug design. Finally, the dosage and safety of AITC require careful evaluation. Although derived from food, high doses of AITC may lead to potential toxicity. Some studies have indicated adverse effects on certain peripheral organs in severely metabolically compromised animal models. Therefore, defining a therapeutic window that is both effective against MASLD and sufficiently safe is a crucial objective for future pre-clinical and clinical research. The development of the derivatives of AITC, a “lead molecule”, may help solve the above problems. The goal is to design compounds that retain liver effects (such as potent VDR activation and Sirt1/AMPKα activation) but reduce the impact on other systems (such as strong TRPA1 stimulation). The clinical applicability of AITC faces multiple obstacles: Unclear oral bioavailability, tissue distribution, and metabolic stability of AITC in humans, all of which require quantification. The dietary intake levels of AITC are likely below the therapeutic thresholds. As with nutraceutical-to-drug conversion, formal dose-ranging toxicology studies are essential to define a safety window—especially given its potential off-target effects (e.g., TRPA1 activation). Compared to single-target agents (e.g., FXR agonists such as obeticholic acid)[24], the multipathway modulation of AITC (VDR/AMPK/NF-κB) addresses the multifactorial nature of MASLD. However, unlike GLP-1 agonists (e.g., tirzepatide)[25] with proven cardiometabolic benefits, the systemic efficacy of AITC remains invalidated.
CONCLUSION
The work by Gao and colleagues is an important piece of research characterized by deep mechanistic exploration and a clear logical progression. It successfully connects a natural compound from the dinner table with a classic hormonal receptor pathway, constructing a novel model to explain how AITC ameliorates MASLD. AITC upregulates and activates the VDR, which in turn drives the HNF-4α/MTTP/ApoB signaling axis, ultimately promoting hepatic lipid export, suppressing lipid synthesis, and enhancing fatty acid oxidation, thereby combating hepatic steatosis through multiple synchronized mechanisms.
This work not only introduces a promising new candidate molecule for MASLD treatment but also, and more importantly, reminds us that in seeking solutions for complex diseases, returning to nature and delving into the multi-targeted actions of natural products, combined with modern molecular biological research, can unveil bioactive potentials in dietary sources, potentially revealing novel therapeutic avenues for complex diseases. It emphasizes that on the path from the discovery at the dining table to the final clinical application, deeply understanding and managing possible off-target effects, optimizing dose schemes to ensure that the liver benefits more than the systemic risks, is a key obstacle that must be overcome in the future. To advance AITC translation, we propose the following preclinical validation: Hepatocyte-specific VDR-KO mice fed high-fat diets to test pathway necessity; toxicology profiling: 28-day dose-range studies in MASLD models to define therapeutic windows; phase 0 trials: And pharmacokinetics and biomarker studies in human MASLD subphenotypes (e.g., diabetics vs non-diabetics). Future research is well-justified to continue exploring this promising path from the dinner table to the liver.
